FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039697777> ?p ?o ?g. }

• W2039697777 endingPage "1433" @default.
• W2039697777 startingPage "1428" @default.
• W2039697777 abstract "Building upon the concept of schedule-specific biochemical modulation of 5-fluorouracil (FU), which alternates bolus and continuous infusion (CI) FU, we have incorporated oxaliplatin (l-OHP) following the bolus part of the regimen to explore the activity of this new combination. Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2)). After 1 week of rest, the second cycle was started. The treatment was continued until progression or patient's refusal. According to the intention-to-treat analysis on all 46 patients accrued, the response rate was 42% (95% CL=28-55%), with three complete responses and 16 partial responses. The median overall survival was 15.9 months and the median progression-free survival 6.9 months. Toxicity was very mild, with the bolus part of the regimen more toxic than the infusional part (24 vs 7% of grade III-IV, respectively). This new combination of MTX -->l-OHP-FU followed by FU CI is well tolerated, feasible and produces activity results similar to other more simple, but more toxic, regimens. Pros and cons of the different fluoropyrimidines-l-OHP combinations are discussed." @default.
• W2039697777 created "2016-06-24" @default.
• W2039697777 creator A5009976972 @default.
• W2039697777 creator A5011308487 @default.
• W2039697777 creator A5032477448 @default.
• W2039697777 creator A5037714306 @default.
• W2039697777 creator A5045260424 @default.
• W2039697777 creator A5051648139 @default.
• W2039697777 creator A5061179981 @default.
• W2039697777 creator A5067202483 @default.
• W2039697777 creator A5069937000 @default.
• W2039697777 creator A5079256460 @default.
• W2039697777 creator A5084773667 @default.
• W2039697777 date "2004-09-21" @default.
• W2039697777 modified "2023-10-06" @default.
• W2039697777 title "Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil" @default.
• W2039697777 cites W121414984 @default.
• W2039697777 cites W1905936368 @default.
• W2039697777 cites W1916504364 @default.
• W2039697777 cites W2019576346 @default.
• W2039697777 cites W2020377538 @default.
• W2039697777 cites W2029409133 @default.
• W2039697777 cites W2041053765 @default.
• W2039697777 cites W2050984109 @default.
• W2039697777 cites W2061500738 @default.
• W2039697777 cites W2070573248 @default.
• W2039697777 cites W2102172720 @default.
• W2039697777 cites W2119112791 @default.
• W2039697777 cites W2121368761 @default.
• W2039697777 cites W2128447158 @default.
• W2039697777 cites W2138926750 @default.
• W2039697777 cites W2141817518 @default.
• W2039697777 cites W2151693072 @default.
• W2039697777 cites W2156128049 @default.
• W2039697777 cites W2156549074 @default.
• W2039697777 cites W2167805334 @default.
• W2039697777 cites W2314927739 @default.
• W2039697777 cites W339474882 @default.
• W2039697777 cites W4293241248 @default.
• W2039697777 doi "https://doi.org/10.1038/sj.bjc.6602176" @default.
• W2039697777 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2409920" @default.
• W2039697777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15381935" @default.
• W2039697777 hasPublicationYear "2004" @default.
• W2039697777 type Work @default.
• W2039697777 sameAs 2039697777 @default.
• W2039697777 citedByCount "2" @default.
• W2039697777 crossrefType "journal-article" @default.
• W2039697777 hasAuthorship W2039697777A5009976972 @default.
• W2039697777 hasAuthorship W2039697777A5011308487 @default.
• W2039697777 hasAuthorship W2039697777A5032477448 @default.
• W2039697777 hasAuthorship W2039697777A5037714306 @default.
• W2039697777 hasAuthorship W2039697777A5045260424 @default.
• W2039697777 hasAuthorship W2039697777A5051648139 @default.
• W2039697777 hasAuthorship W2039697777A5061179981 @default.
• W2039697777 hasAuthorship W2039697777A5067202483 @default.
• W2039697777 hasAuthorship W2039697777A5069937000 @default.
• W2039697777 hasAuthorship W2039697777A5079256460 @default.
• W2039697777 hasAuthorship W2039697777A5084773667 @default.
• W2039697777 hasBestOaLocation W20396977771 @default.
• W2039697777 hasConcept C121608353 @default.
• W2039697777 hasConcept C126322002 @default.
• W2039697777 hasConcept C141071460 @default.
• W2039697777 hasConcept C143998085 @default.
• W2039697777 hasConcept C2776694085 @default.
• W2039697777 hasConcept C2778397455 @default.
• W2039697777 hasConcept C2780456651 @default.
• W2039697777 hasConcept C2780962732 @default.
• W2039697777 hasConcept C2781059491 @default.
• W2039697777 hasConcept C2781413609 @default.
• W2039697777 hasConcept C29730261 @default.
• W2039697777 hasConcept C31760486 @default.
• W2039697777 hasConcept C43376680 @default.
• W2039697777 hasConcept C526805850 @default.
• W2039697777 hasConcept C71924100 @default.
• W2039697777 hasConcept C90924648 @default.
• W2039697777 hasConceptScore W2039697777C121608353 @default.
• W2039697777 hasConceptScore W2039697777C126322002 @default.
• W2039697777 hasConceptScore W2039697777C141071460 @default.
• W2039697777 hasConceptScore W2039697777C143998085 @default.
• W2039697777 hasConceptScore W2039697777C2776694085 @default.
• W2039697777 hasConceptScore W2039697777C2778397455 @default.
• W2039697777 hasConceptScore W2039697777C2780456651 @default.
• W2039697777 hasConceptScore W2039697777C2780962732 @default.
• W2039697777 hasConceptScore W2039697777C2781059491 @default.
• W2039697777 hasConceptScore W2039697777C2781413609 @default.
• W2039697777 hasConceptScore W2039697777C29730261 @default.
• W2039697777 hasConceptScore W2039697777C31760486 @default.
• W2039697777 hasConceptScore W2039697777C43376680 @default.
• W2039697777 hasConceptScore W2039697777C526805850 @default.
• W2039697777 hasConceptScore W2039697777C71924100 @default.
• W2039697777 hasConceptScore W2039697777C90924648 @default.
• W2039697777 hasIssue "8" @default.
• W2039697777 hasLocation W20396977771 @default.
• W2039697777 hasLocation W20396977772 @default.
• W2039697777 hasLocation W20396977773 @default.
• W2039697777 hasLocation W20396977774 @default.
• W2039697777 hasOpenAccess W2039697777 @default.
• W2039697777 hasPrimaryLocation W20396977771 @default.

• next